abstract |
The present invention relates to N-{(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxyindol-5-phenyl-2,3) ,4,5-tetrahydro-1,5-benzothiazepine-8-yl]oxy}ethenyl)amino]-2-phenylethanol}glycolic acid (elobixibat) Crystalline modifications, more specifically crystalline modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to methods of preparing such crystalline modifications and pharmaceutical compositions comprising crystalline modification IV. |